PD-1 Inhibitors + CAR T Cell Therapy for Hodgkin's Lymphoma

Recruiting in Palo Alto (17 mi)

Overseen byNatalie S. Grover

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: UNC Lineberger Comprehensive Cancer Center

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to achieve clinical responses in subjects with relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL).

Eligibility Criteria

This trial is for adults over 18 with classical Hodgkin lymphoma that's come back or hasn't responded to treatment. They must have tried at least three prior therapies and either had or not had CD30 CAR-T therapy. Participants need to give informed consent, be ready for standard anti-PD-1 therapy, and provide blood samples.

Inclusion Criteria

I am 18 years old or older.

I have been diagnosed with classical Hodgkin lymphoma.

I am starting standard anti-PD-1 therapy as advised by my oncologist.

See 7 more

Treatment Details

Interventions

Nivolumab (PD-1 Inhibitor)
Pembrolizumab (PD-1 Inhibitor)

Trial OverviewThe study is testing if CAR-T cell therapy can make the immune system respond better to PD-1 inhibitors like Nivolumab and Pembrolizumab in patients with relapsed/refractory Hodgkin lymphoma. It has two groups: one previously treated with CD30 CAR-T cells and one without such treatment.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Arm 2: Relapse with no Prior CD30 CAR-T TherapyExperimental Treatment2 Interventions

Subjects with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who have previously progressed on anti-PD-1 therapy, have not received a CD30 CAR-T cell therapy and have evidence of progression. Subjects will be offered anti-PD-1 therapy (nivolumab or pembrolizumab, at the discretion of treating oncologist), as per standard of care in r/r cHL.

Group II: Arm 1: Relapse After Prior CD30 CAR-T TherapyExperimental Treatment2 Interventions

Subjects with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who have previously progressed on anti-PD-1 therapy, have received a CD30 CAR-T cell therapy and have evidence of progression. Subjects will be offered anti-PD-1 therapy (nivolumab or pembrolizumab, at the discretion of treating oncologist), as per standard of care in r/r cHL.